Janus Henderson Group PLC Takes $11.29 Million Position in Monte Rosa Therapeutics, Inc. $GLUE

Janus Henderson Group PLC bought a new stake in shares of Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 685,926 shares of the company’s stock, valued at approximately $11,294,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Vanguard Group Inc. increased its stake in Monte Rosa Therapeutics by 8.6% in the 4th quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock worth $50,905,000 after purchasing an additional 257,547 shares during the period. Swiss National Bank purchased a new stake in shares of Monte Rosa Therapeutics during the first quarter valued at approximately $1,005,000. Arrowstreet Capital Limited Partnership boosted its stake in shares of Monte Rosa Therapeutics by 110.5% during the first quarter. Arrowstreet Capital Limited Partnership now owns 647,739 shares of the company’s stock valued at $10,655,000 after purchasing an additional 340,088 shares during the period. Exome Asset Management LLC bought a new position in shares of Monte Rosa Therapeutics in the first quarter worth approximately $2,953,000. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Monte Rosa Therapeutics by 1,355.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 392,227 shares of the company’s stock worth $6,452,000 after purchasing an additional 365,272 shares during the last quarter. 79.96% of the stock is currently owned by institutional investors.

Monte Rosa Therapeutics Stock Performance

GLUE opened at $16.08 on Wednesday. The stock has a market capitalization of $1.36 billion, a PE ratio of -10.86 and a beta of 1.59. The stock’s 50 day moving average price is $20.75 and its 200-day moving average price is $19.49. Monte Rosa Therapeutics, Inc. has a 52-week low of $4.12 and a 52-week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.06). The business had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $10.95 million. Monte Rosa Therapeutics had a negative return on equity of 40.99% and a negative net margin of 302.69%. Research analysts forecast that Monte Rosa Therapeutics, Inc. will post -1.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on GLUE. Guggenheim upped their price target on shares of Monte Rosa Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Weiss Ratings raised shares of Monte Rosa Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, July 28th. Wedbush decreased their price objective on shares of Monte Rosa Therapeutics from $37.00 to $27.00 and set an “outperform” rating on the stock in a research report on Monday. Jefferies Financial Group reaffirmed a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Monday, July 27th. Finally, Zacks Research lowered shares of Monte Rosa Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, July 6th. Seven equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Monte Rosa Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $30.67.

Insider Activity at Monte Rosa Therapeutics

In other news, Director Anthony M. Manning sold 10,000 shares of the firm’s stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $23.11, for a total value of $231,100.00. Following the completion of the sale, the director directly owned 10,000 shares of the company’s stock, valued at approximately $231,100. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Filip Janku sold 30,000 shares of Monte Rosa Therapeutics stock in a transaction dated Wednesday, June 24th. The shares were sold at an average price of $21.42, for a total transaction of $642,600.00. Following the sale, the insider directly owned 59,992 shares in the company, valued at $1,285,028.64. The trade was a 33.34% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 81,778 shares of company stock valued at $1,768,581 over the last quarter. Company insiders own 6.40% of the company’s stock.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.